Literature DB >> 19483056

Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy.

M M Hoeper, K M Olsson, A Schneider, H Golpon.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19483056     DOI: 10.1183/09031936.00193308

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  6 in total

Review 1.  Treatment of pulmonary arterial hypertension in children.

Authors:  Heiner Latus; Tammo Delhaas; Dietmar Schranz; Christian Apitz
Journal:  Nat Rev Cardiol       Date:  2015-02-03       Impact factor: 32.419

2.  Effectiveness of phosphodiesterase-5 inhibitor therapy for portopulmonary hypertension.

Authors:  Jolene H Fisher; Sindhu R Johnson; Cathy Chau; Amie T Kron; John T Granton
Journal:  Can Respir J       Date:  2014-12-18       Impact factor: 2.409

3.  Sitaxsentan-induced acute severe hepatitis treated with glucocorticoid therapy.

Authors:  Marcus Chin; Robert D Levy; Eric M Yoshida; Michaeal F Byrne
Journal:  Can Respir J       Date:  2012 Jan-Feb       Impact factor: 2.409

4.  Pathologic role of stressed-induced glucocorticoids in drug-induced liver injury in mice.

Authors:  Mary Jane Masson; Lindsay A Collins; Leah D Carpenter; Mary L Graf; Pauline M Ryan; Mohammed Bourdi; Lance R Pohl
Journal:  Biochem Biophys Res Commun       Date:  2010-05-27       Impact factor: 3.575

Review 5.  The Role of Endothelin and Endothelin Antagonists in Chronic Kidney Disease.

Authors:  Rupesh Raina; Abigail Chauvin; Ronith Chakraborty; Nikhil Nair; Haikoo Shah; Vinod Krishnappa; Kirsten Kusumi
Journal:  Kidney Dis (Basel)       Date:  2019-12-18

Review 6.  Endothelin Blockade in Diabetic Kidney Disease.

Authors:  Lidia Anguiano; Marta Riera; Julio Pascual; María José Soler
Journal:  J Clin Med       Date:  2015-05-25       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.